Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics

Kiniksa Pharmaceuticals, Ltd. - (KNSA)

Today's Latest Price: $19.19 USD

0.25 (-1.29%)

Updated Jan 28 11:15am

Add KNSA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 241 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KNSA Stock Price Chart Interactive Chart >

Price chart for KNSA

KNSA Price/Volume Stats

Current price $19.19 52-week high $28.67
Prev. close $19.44 52-week low $10.30
Day low $19.01 Volume 41,515
Day high $20.00 Avg. volume 284,588
50-day MA $18.17 Dividend yield N/A
200-day MA $19.13 Market Cap 1.31B

Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda

KNSA Latest News Stream

Event/Time News Detail
Loading, please wait...

KNSA Latest Social Stream

Loading social stream, please wait...

View Full KNSA Social Stream

Latest KNSA News From Around the Web

Below are the latest news stories about Kiniksa Pharmaceuticals Ltd that investors may wish to consider to help them evaluate KNSA as an investment opportunity.

New Strong Sell Stocks for January 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Yahoo | January 27, 2021

Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the…

GlobeNewswire | January 4, 2021

Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation

\- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab – \- Data from the Phase 2 portion of Kiniksa’s adaptive design Phase 2/3 clinical trial expected in 1H 2021 -HAMILTON, Bermuda, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced data from the investigator-initiated placebo-controlled study of mavrilimumab in patients with severe COVID-19 pneumonia and hyperinflammation. Enrollment in the study was closed early to focus on Kiniksa’s registrational development program in the same patient population.“The data...

Yahoo | December 22, 2020

Is KNSA A Good Stock To Buy Now?

We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) based on that […]

Yahoo | December 18, 2020

Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis

– Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously –HAMILTON, Bermuda, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the commencement of dosing in the Phase 2b clinical trial of vixarelimab in prurigo nodularis, a chronic inflammatory skin condition characterized by severely pruritic skin nodules. Vixarelimab is a fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ). The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis in...

Yahoo | December 15, 2020

Read More 'KNSA' Stories Here

KNSA Price Returns

1-mo 9.41%
3-mo 22.54%
6-mo -1.69%
1-year 28.10%
3-year N/A
5-year N/A
YTD 8.60%
2020 59.76%
2019 -60.63%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.3606 seconds.